Literature DB >> 25690979

Transplantation of PEDF-transfected pigment epithelial cells inhibits corneal neovascularization in a rabbit model.

David Kuerten1, Sandra Johnen, Nina Harmening, George Souteyrand, Peter Walter, Gabriele Thumann.   

Abstract

BACKGROUND: The purpose of this study was to investigate the effect of recombinant pigment epithelium-derived factor (rPEDF), secreted by ARPE-19 cells transfected with the human PEDF gene and transplanted subconjunctivally in normal and in rabbits in which corneal neovascularization was elicited by a chemical burn.
METHODS: Twenty grey Chinchilla Bastard rabbits were randomly assigned to four groups; neovascularization was induced in groups A, B, and C by alkali cauterization. Seven days later, group A received no cell implantation, non-transfected ARPE-19 cells were implanted subconjunctivally in group B, and PEDF-transfected ARPE-19 cells were implanted subconjunctivally in groups C and D (non-cauterized). In-vivo rPEDF secretion was analyzed by immunoblotting, and ELISA of extracts of conjunctival tissue samples taken at different time points. Digital photographs acquired on days 7, 14, and 21 after cauterization were evaluated for lead vessel length, vascular invasion area, and overall neovascularization rate.
RESULTS: At days 14 and 21 after cauterization, significant differences were observed between groups A, B, and C in lead vessel length (day 21: 5.91 ± 0.45, 5.11 ± 1.22, 3.79 ± 0.59 mm, repectively), vascular invasion area (day 21: 35.5 ± 8.65, 34.86 ± 4.92, 19.2 ± 5.03 mm(2) respectively), and rate of corneal neovascularization. Compared to controls, neovascularization was reduced by 37.5 % on day 14 and 47 % on day 21. Analysis of conjunctival tissue extracts showed that rPEDF was secreted by the transplanted PEDF-transfected cells.
CONCLUSION: Subconjunctivally transplanted, PEDF-transfected ARPE-19 cells secrete rPEDF, which inhibits the corneal neovascularization elicited by alkali cauterization.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25690979     DOI: 10.1007/s00417-015-2954-x

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  54 in total

1.  Sleeping Beauty transposon-mediated transfection of retinal and iris pigment epithelial cells.

Authors:  Sandra Johnen; Zsuzsanna Izsvák; Michael Stöcker; Nina Harmening; Anna Katharina Salz; Peter Walter; Gabriele Thumann
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-07-18       Impact factor: 4.799

2.  Subconjunctival bevacizumab injection for corneal neovascularization.

Authors:  Irit Bahar; Igor Kaiserman; Penny McAllum; David Rootman; Allan Slomovic
Journal:  Cornea       Date:  2008-02       Impact factor: 2.651

3.  Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model.

Authors:  Juan J Pérez-Santonja; Ezequiel Campos-Mollo; Mariola Lledó-Riquelme; Jaime Javaloy; Jorge L Alió
Journal:  Am J Ophthalmol       Date:  2010-06-29       Impact factor: 5.258

4.  Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.

Authors:  D W Dawson; O V Volpert; P Gillis; S E Crawford; H Xu; W Benedict; N P Bouck
Journal:  Science       Date:  1999-07-09       Impact factor: 47.728

5.  Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1.

Authors:  Jun Cai; Wen G Jiang; Maria B Grant; Mike Boulton
Journal:  J Biol Chem       Date:  2005-12-08       Impact factor: 5.157

6.  Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty.

Authors:  C Cursiefen; H Wenkel; P Martus; A Langenbucher; N X Nguyen; B Seitz; M Küchle; G O Naumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2001-07       Impact factor: 3.117

7.  Polyethylene glycol-modified pigment epithelial-derived factor: new prospects for treatment of retinal neovascularization.

Authors:  Yu-Jing Bai; Lv-Zhen Huang; Xiao-Lei Xu; Wei Du; Ai-Yi Zhou; Wen-Zhen Yu; Xiao-Xin Li
Journal:  J Pharmacol Exp Ther       Date:  2012-04-10       Impact factor: 4.030

8.  Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial.

Authors:  Constantinos Petsoglou; Kamaljit S Balaggan; John K G Dart; Catey Bunce; Wen Xing; Robin R Ali; Stephen J Tuft
Journal:  Br J Ophthalmol       Date:  2012-10-20       Impact factor: 4.638

9.  Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.

Authors:  Felix Bock; Yanyan König; Friedrich Kruse; Martin Baier; Claus Cursiefen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-10-13       Impact factor: 3.117

10.  Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican.

Authors:  S Chakravarti; T Magnuson; J H Lass; K J Jepsen; C LaMantia; H Carroll
Journal:  J Cell Biol       Date:  1998-06-01       Impact factor: 10.539

View more
  4 in total

Review 1.  Molecular underpinnings of corneal angiogenesis: advances over the past decade.

Authors:  Nizar Saleh Abdelfattah; Mohamed Amgad; Amira A Zayed; Heba Hussein; Nawal Abd El-Baky
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

Review 2.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

3.  Engineering of PEDF-Expressing Primary Pigment Epithelial Cells by the SB Transposon System Delivered by pFAR4 Plasmids.

Authors:  Gabriele Thumann; Nina Harmening; Cécile Prat-Souteyrand; Corinne Marie; Marie Pastor; Attila Sebe; Csaba Miskey; Laurence D Hurst; Sabine Diarra; Martina Kropp; Peter Walter; Daniel Scherman; Zoltán Ivics; Zsuzsanna Izsvák; Sandra Johnen
Journal:  Mol Ther Nucleic Acids       Date:  2017-02-10       Impact factor: 8.886

4.  The Antibiotic-free pFAR4 Vector Paired with the Sleeping Beauty Transposon System Mediates Efficient Transgene Delivery in Human Cells.

Authors:  Marie Pastor; Sandra Johnen; Nina Harmening; Mickäel Quiviger; Julie Pailloux; Martina Kropp; Peter Walter; Zoltán Ivics; Zsuzsanna Izsvák; Gabriele Thumann; Daniel Scherman; Corinne Marie
Journal:  Mol Ther Nucleic Acids       Date:  2017-12-30       Impact factor: 8.886

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.